ContraFect Plans To Present New Data Demonstrating Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens At ASM Microbe 2023
Portfolio Pulse from Benzinga Newsdesk
ContraFect plans to present new data at ASM Microbe 2023, demonstrating the potential efficacy of its engineered lysins, CF-370, against antibiotic-resistant pathogens, specifically an extensively-drug-resistant strain of Klebsiella pneumoniae.
June 08, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ContraFect's presentation of new data on CF-370's potential efficacy against antibiotic-resistant pathogens may positively impact its stock price.
The presentation of new data on CF-370's potential efficacy against antibiotic-resistant pathogens is highly relevant to ContraFect's core business. Positive results may increase investor confidence in the company's product pipeline and drive the stock price up.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100